drugset / Trial / NCT00147537
Combination Study Of CP-751,871 With Paclitaxel And Carboplatin In Advanced Lung Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
Phase 1b Dose Excalation/Expansion: Identify and characterize safety and tolerability of recommended phase 2 dose of CP-751,871 when administered with paclitaxel and carboplatin Phase 1b Erlotinib Extension: To characterize the safety and tolerability of CP751,871 when administered with paclitaxel, carboplatin and erlotinib. Phase 2: To test the efficacy of CP-751,871 combined with paclitaxel and carboplatin in the treatment of advanced non-small cell lung cancer
Timeline
- Start
- 2005-02
- Primary completion
- 2011-08
- Completion
- 2011-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | 6 unknown | Intravenous |
| Subject | Erlotinib | Small molecule | 150 mg | Oral |
| Subject | Figitumumab | Monoclonal antibody | 20 mg/kg | Intravenous |
| Subject | Paclitaxel | Small molecule | 200 mg/m2 | Intravenous |